Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -4735.97% is 79% above its 1-year average of -22407.94%, near the high end of its 1-year range (-119957.88%–18831.50%).
78.86% above its 12-month average of -22407.94%.
Reported quarterly EBITDA margin; no daily interpolation. Q3 FY2026 (2026-06-30): -119957.88%.
EBITDA MARGIN
-4735.97%
EBITDA MARGIN AVG TTM
-22407.94%
EBITDA MARGIN AVG 3Y
-22407.94%
EBITDA MARGIN AVG 5Y
-22407.94%
EBITDA MARGIN AVG 10Y
-1152.46%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+78.86%
CURRENT VS 3Y AVG
+78.86%
CURRENT VS 5Y AVG
+78.86%
CURRENT VS 10Y AVG
-310.94%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Outlook Therapeutics, Inc.
Market Cap
$109.34M
EBITDA Margin
-4735.97%
TTM Avg
-22407.94%
3Y Avg
-22407.94%
5Y Avg
-22407.94%
Market Cap
$110.33M
EBITDA Margin
-10.96%
TTM Avg
-24.45%
3Y Avg
-32.87%
5Y Avg
-38.11%
Market Cap
$108.11M
EBITDA Margin
-6164.17%
TTM Avg
-4620.17%
3Y Avg
-2654.54%
5Y Avg
-2163.85%
Market Cap
$109.02M
EBITDA Margin
-624817.90%
TTM Avg
-624817.90%
3Y Avg
-624817.90%
5Y Avg
-624817.90%
Market Cap
$108.84M
EBITDA Margin
28.85%
TTM Avg
28.85%
3Y Avg
28.85%
5Y Avg
28.85%
Market Cap
$111.27M
EBITDA Margin
-29.32%
TTM Avg
-13.32%
3Y Avg
-6.17%
5Y Avg
-1.07%
Market Cap
$111.61M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$106.08M
EBITDA Margin
5.60%
TTM Avg
2.28%
3Y Avg
0.00%
5Y Avg
-2.15%
Market Cap
$105.27M
EBITDA Margin
6.31%
TTM Avg
-127.53%
3Y Avg
-89.97%
5Y Avg
-50.55%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | $109.34M | -4735.97% | -22407.94% | -22407.94% | -22407.94% |
| Apyx Medical Corporation (APYX)vs › | $110.33M | -10.96% | -24.45% | -32.87% | -38.11% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.11M | -6164.17% | -4620.17% | -2654.54% | -2163.85% |
| Immunic, Inc. (IMUX)vs › | $109.02M | -624817.90% | -624817.90% | -624817.90% | -624817.90% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $108.84M | 28.85% | 28.85% | 28.85% | 28.85% |
| BGM Group Ltd. (BGM)vs › | $111.27M | -29.32% | -13.32% | -6.17% | -1.07% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $111.61M | N/A | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.08M | 5.60% | 2.28% | 0.00% | -2.15% |
| Definitive Healthcare Corp. (DH)vs › | $105.27M | 6.31% | -127.53% | -89.97% | -50.55% |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | -121.55% | -120.84% | -101.07% | -82.00% |
Gross Margin
46.5%
EBITDA Margin
-4736.0%
Operating Margin
-4744.3%
Net Margin
-4416.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -119957.88% |
| 2026-03-31 | -10982.96% |
| 2025-12-31 | 1113.89% |
| 2025-09-30 | 18831.50% |
| 2025-06-30 | -1044.25% |
| 2019-09-30 | -201.63% |
| 2019-06-30 | -823.95% |
| 2019-03-31 | -1074.56% |
| 2018-12-31 | -883.33% |
| 2018-09-30 | -1501.46% |
| 2018-06-30 | -828.87% |
| 2018-03-31 | -790.23% |
| 2017-12-31 | -324.32% |
| 2017-09-30 | -66.57% |
| 2017-06-30 | -2198.29% |
| 2017-03-31 | -2361.24% |
| 2016-12-31 | -5649.28% |
| 2016-09-30 | -1972.22% |
| 2016-06-30 | -4329.89% |
| 2016-03-31 | -236.80% |
| 2015-12-31 | -1590.02% |
| 2015-09-30 | -3315.79% |
| 2015-06-30 | -820.45% |
| 2015-03-31 | -2785.04% |
| 2014-12-31 | -133.59% |
